Sex differences in psychiatric comorbidity and plasma biomarkers for cocaine addiction in abstinent cocaine-addicted subjects in outpatient settings

Frontiers in Psychiatry

Volumn 6, Issue FEB, 2015, Pages

  Pedraz, María ^a   Araos, Pedro ^a   García Marchena, Nuria ^a   Serrano, Antonia ^a   Romero Sanchiz, Pablo ^a   Suárez, Juan ^a   Castilla Ortega, Estela ^a   Mayoral Cleries, Fermín ^a   Ruiz, Juan Jesús ^b   Pastor, Antoni ^c,d   Barrios, Vicente ^e,f   Chowen, Julie A ^e,f   Argente, Jesús ^e,f   Torrens, Marta ^c,d,g   De la Torre, Rafael ^c,f,h   De Fonseca, Fernando Rodríguez ^a,f   Pavón, Francisco Javier ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b Centro Provincial de Drogodependencia Diputación de Málaga   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g Institut de Neuropsiquiatria i Addiccions (INAD) Parc de Salut Mar   (Spain)

^h UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Abstinence; Biomarker; Cocaine use disorders; Cytokine; Endocannabinoid; Outpatient; Psychiatric comorbidity; Sex

Indexed keywords

2 ACYL GLYCEROL; ALPHA CHEMOKINE; BENZOYLECGONINE; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; FATTY ACID DERIVATIVE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; N ACYL ETHANOLAMINE; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ALCOHOL USE DISORDER; ANXIETY DISORDER; ARTICLE; BODY MASS; COCAINE DEPENDENCE; COHABITING PERSON; COMORBIDITY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE DURATION; EDUCATIONAL STATUS; EMPLOYMENT STATUS; FEMALE; HELP SEEKING BEHAVIOR; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MENTAL DISEASE; MOOD DISORDER; OUTPATIENT; PERSONALITY DISORDER; PREVALENCE; PSYCHOSIS; SEX DIFFERENCE;

EID: 84926675012     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2015.00017     Document Type: Article

References (51)

1. EMCDDA. Annual report 2012: the state of the drugs problem in Europe. Euro Surveill (2012) 17:20315.
2. Andersen ML, Sawyer EK, Howell LL. Contributions of neuroimaging to understanding sex differences in cocaine abuse. Exp Clin Psychopharmacol (2012) 20:2-15. doi: 10.1037/a0025219
3. Becker JB, Hu M. Sex differences in drug abuse. Front Neuroendocrinol (2008) 29:36-47. doi:10.1016/j.yfrne.2007.07.003
4. Kennedy AP, Epstein DH, Phillips KA, Preston KL. Sex differences in cocaine/heroin users: drug-use triggers and craving in daily life. Drug Alcohol Depend (2013) 132:29-37. doi:10.1016/j.drugalcdep.2012.12.025
5. Bobzean SA, Denobrega AK, Perrotti LI. Sex differences in the neurobiology of drug addiction. Exp Neurol (2014) 259:64-74. doi:10.1016/j.expneurol.2014.01.022
6. Quinones-Jenab V, Jenab S. Influence of sex differences and gonadal hormones on cocaine addiction. ILAR J (2012) 53:14-22. doi:10.1093/ilar.53.1.14
7. Robbins SJ, Ehrman RN, Childress AR, O'Brien CP. Comparing levels of cocaine cue reactivity in male and female outpatients. Drug Alcohol Depend (1999) 53:223-30. doi:10.1016/S0376-8716(98)00135-5
8. Winhusen T, Lewis D. Sex differences in disinhibition and its relationship to physical abuse in a sample of stimulant-dependent patients. Drug Alcohol Depend (2013) 129:158-62. doi:10.1016/j.drugalcdep.2012.09.014
9. Back SE, Brady KT, Jackson JL, Salstrom S, Zinzow H. Gender differences in stress reactivity among cocaine-dependent individuals. Psychopharmacology (Berl) (2005) 180:169-76. doi:10.1007/s00213-004-2129-7
10. Festa ED, Quinones-Jenab V. Gonadal hormones provide the biological basis for sex differences in behavioral responses to cocaine. Horm Behav (2004) 46:509-19. doi:10.1016/j.yhbeh.2004.04.009
11. Herrero MJ, Domingo-Salvany A, Torrens M, Brugal MT. Psychiatric comorbidity in young cocaine users: induced versus independent disorders. Addiction (2008) 103:284-93. doi:10.1111/j.1360-0443.2007.02076.x
12. Araos P, Vergara-Moragues E, Pedraz M, Pavon FJ, Campos Cloute R, Calado M, et al. [Psychopathological comorbidity in cocaine users in outpatient treatment]. Adicciones (2014) 26:15-26.
13. Fattore L, Altea S, Fratta W. Sex differences in drug addiction: a review of animal and human studies. Womens Health (Lond Engl) (2008) 4:51-65. doi:10.2217/17455057.4.1.51
14. Greenfield SF, Back SE, Lawson K, Brady KT. Substance abuse in women. Psychiatr Clin North Am (2010) 33:339-55. doi:10.1016/j.psc.2010.01.004
15. Fernandez-Guasti A, Fiedler JL, Herrera L, Handa RJ. Sex, stress, and mood disorders: at the intersection of adrenal and gonadal hormones. Horm Metab Res (2012) 44:607-18. doi:10.1055/s-0032-1312592
16. Domenici E, Muglia P. The search for peripheral disease markers in psychiatry by genomic and proteomic approaches. Expert Opin Med Diagn (2007) 1:235-51. doi:10.1517/17530059.1.2.235
17. Domenici E, Wille DR, Tozzi F, Prokopenko I, Miller S, McKeown A, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One (2010) 5:e9166. doi:10.1371/journal.pone.0009166
18. Sinha R. New findings on biological factors predicting addiction relapse vulnerability. Curr Psychiatry Rep (2011) 13:398-405. doi:10.1007/s11920-011-0224-0
19. Pavon FJ, Araos P, Pastor A, Calado M, Pedraz M, Campos-Cloute R, et al. Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity. Addict Biol (2013) 18:955-69. doi:10.1111/adb.12107
20. Araos P, Pedraz M, Serrano A, Lucena M, Barrios V, Garcia-Marchena N, et al. Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatient treatment: influence of cocaine symptom severity and psychiatric co-morbidity. Addict Biol (2014). doi:10.1111/adb.12156
21. Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, Endicott J. Psychiatric research interview for substance and mental disorders (PRISM): reliability for substance abusers. Am J Psychiatry (1996) 153:1195-201. doi:10.1176/ajp.153.9.1195
22. Torrens M, Serrano D, Astals M, Perez-Dominguez G, Martin-Santos R. Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the psychiatric research interview for substance and mental disorders and the structured clinical interview for DSM-IV. Am J Psychiatry (2004) 161:1231-7. doi:10.1176/appi.ajp.161.7.1231
23. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, et al. The composite international diagnostic interview - an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry (1988) 45:1069-77. doi:10.1001/archpsyc.1988.01800360017003
24. Hasin D, Samet S, Nunes E, Meydan J, Matseoane K, Waxman R. Diagnosis of comorbid psychiatric disorders in substance users assessed with the psychiatric research interview for substance and mental disorders for DSM-IV. Am J Psychiatry (2006) 163:689-96. doi:10.1176/appi.ajp.163.4.689
25. Morgello S, Holzer CE III, Ryan E, Young C, Naseer M, Castellon SA, et al. Interrater reliability of the psychiatric research interview for substance and mental disorders in an HIV-infected cohort: experience of the National NeuroAIDS Tissue Consortium. Int J Methods Psychiatr Res (2006) 15:131-8. doi:10.1002/mpr.189
26. Rivera P, Luque-Rojas MJ, Pastor A, Blanco E, Pavon FJ, Serrano A, et al. Diet-dependent modulation of hippocampal expression of endocannabinoid signaling-related proteins in cannabinoid antagonist-treated obese rats. Eur J Neurosci (2013) 37:105-17. doi:10.1111/ejn.12012
27. Vergara-Moragues E, Gonzalez-Saiz F, Lozano OM, Betanzos Espinosa P, Fernandez Calderon F, Bilbao-Acebos I, et al. Psychiatric comorbidity in cocaine users treated in therapeutic community: substance-induced versus independent disorders. Psychiatry Res (2012) 200:734-41. doi:10.1016/j.psychres.2012.07.043
28. Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry (2006) 67:247-57. doi:10.4088/JCP.v67n0211
29. Schuurs AH, Verheul HA. Effects of gender and sex steroids on the immune response. J Steroid Biochem (1990) 35:157-72. doi:10.1016/0022-4731(90)90270-3
30. Kovacs EJ, Messingham KA. Influence of alcohol and gender on immune response. Alcohol Res Health (2002) 26:257-63.
31. Coller JK, Hutchinson MR. Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence. Pharmacol Ther (2012) 134:219-45. doi:10.1016/j.pharmthera.2012.01.008
32. Trecki J, Unterwald EM. Modulation of cocaine-induced activity by intracerebral administration of CXCL12. Neuroscience (2009) 161:13-22. doi:10.1016/j.neuroscience.2009.03.027
33. Crews FT, Zou J, Qin L. Induction of innate immune genes in brain create the neurobiology of addiction. Brain Behav Immun (2011) 25(Suppl 1):S4-12. doi:10.1016/j.bbi.2011.03.003
34. Stuart MJ, Baune BT. Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neurosci Biobehav Rev (2014) 42:93-115. doi:10.1016/j.neubiorev.2014.02.001
35. Achur RN, Freeman WM, Vrana KE. Circulating cytokines as biomarkers of alcohol abuse and alcoholism. J Neuroimmune Pharmacol (2010) 5:83-91. doi:10.1007/s11481-009-9185-z
36. Irwin MR, Olmos L, Wang M, Valladares EM, Motivala SJ, Fong T, et al. Cocaine dependence and acute cocaine induce decreases of monocyte proinflammatory cytokine expression across the diurnal period: autonomic mechanisms. J Pharmacol Exp Ther (2007) 320:507-15. doi:10.1124/jpet.106.112797
37. Salim S, Chugh G, Asghar M. Inflammation in anxiety. Adv Protein Chem Struct Biol (2012) 88:1-25. doi:10.1016/B978-0-12-398314-5.00001-5
38. Serrano A, Parsons LH. Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther (2011) 132:215-41. doi:10.1016/j.pharmthera.2011.06.005
39. Bilbao A, Blanco E, Luque-Rojas MJ, Suarez J, Palomino A, Vida M, et al. Oleoylethanolamide dose-dependently attenuates cocaine-induced behaviours through a PPARalpha receptor-independent mechanism. Addict Biol (2013) 18:78-87. doi:10.1111/adb.12006
40. Potvin S, Kouassi E, Lipp O, Bouchard RH, Roy MA, Demers MF, et al. Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. J Psychopharmacol (2008) 22:262-9. doi:10.1177/0269881107083816
41. Desfosses J, Stip E, Bentaleb LA, Lipp O, Chiasson JP, Furtos A, et al. Plasma endocannabinoid alterations in individuals with substance use disorder are dependent on the "mirror effect" of schizophrenia. Front Psychiatry (2012) 3:85. doi:10.3389/fpsyt.2012.00085
42. Mangieri RA, Hong KI, Piomelli D, Sinha R. An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics. Psychopharmacology (Berl) (2009) 205:63-72. doi:10.1007/s00213-009-1518-3
43. Feuerecker M, Hauer D, Gresset T, Lassas S, Kaufmann I, Vogeser M, et al. Effect of an acute consumption of a moderate amount of ethanol on plasma endocannabinoid levels in humans. Alcohol Alcohol (2012) 47:226-32. doi:10.1093/alcalc/agr162
44. Gonzalez S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, Ramos JA. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res (2002) 954:73-81. doi:10.1016/S0006-8993(02)03344-9
45. Caille S, Alvarez-Jaimes L, Polis I, Stouffer DG, Parsons LH. Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci (2007) 27:3695-702. doi:10.1523/JNEUROSCI.4403-06.2007
46. Lambert DM, Muccioli GG. Endocannabinoids and related N-acylethanolamines in the control of appetite and energy metabolism: emergence of new molecular players. Curr Opin Clin Nutr Metab Care (2007) 10:735-44. doi:10.1097/MCO.0b013e3282f00061
47. Syed SK, Bui HH, Beavers LS, Farb TB, Ficorilli J, Chesterfield AK, et al. Regulation of GPR119 receptor activity with endocannabinoid-like lipids. Am J Physiol Endocrinol Metab (2012) 303:E1469-78. doi:10.1152/ajpendo.00269.2012
48. Mozaffarian D, Cao H, King IB, Lemaitre RN, Song X, Siscovick DS, et al. Circulating palmitoleic acid and risk of metabolic abnormalities and new-onset diabetes. Am J Clin Nutr (2010) 92:1350-8. doi:10.3945/ajcn.110.003970
49. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis (2003) 2:5. doi:10.1186/1476-511X-2-5
50. Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry (2008) 41:48-53. doi:10.1055/s-2007-993211
51. Schwarz E, Whitfield P, Nahnsen S, Wang L, Major H, Leweke FM, et al. Alterations of primary fatty acid amides in serum of patients with severe mental illness. Front Biosci (Elite Ed) (2011) 3:308-14. doi:10.2741/e246